Evidence map›Paper›PMID 40457240›Full record

ArticleBMC infectious diseases2025

HIV-1 diagnostic, prognostic and ART-resistance detection potential of selected MiRNAs.

Karen Pomeyie, Joseph Humphrey Kofi Bonney, Benjamin Amoani, Roland Osei Saahene, Nicholas Ekow Thomford, Wishwell Pomeyie, Francis Abrokwah, Helena Quayson, Salisu Kalaamullah Musah, Selina Appiah and 4 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Karen PomeyieVirology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Joseph Humphrey Kofi BonneyVirology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Benjamin AmoaniDepartment of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Roland Osei SaaheneDepartment of Microbiology and Immunology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Nicholas Ekow ThomfordPharmacogenomics and Genomic Medicine Group, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Wishwell PomeyieDepartment of Physician Assistantship, School of Medical Sciences, Central University College, Accra, Ghana.
Francis AbrokwahDepartment of Biochemistry, School of Biological Sciences, University of Cape Coast, Cape Coast, Ghana.
Helena QuaysonDepartment of Microbiology and Immunology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.
Salisu Kalaamullah MusahVirology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Selina AppiahPhlebotomy Unit, Cape Coast Teaching Hospital, Cape Coast, Ghana.
Deborah PrattVirology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Magdalene Sarah OforiVirology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Alexander Owusu-AnsahImmunology and Serology Department, Cape Coast Teaching Hospital, Cape Coast, Ghana.
Prince Amoah BarnieDepartment of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast, Ghana. pamoah-barnie@ucc.edu.gh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global HIV prevalence estimate at the end of 2022 was 39 million. This has led to mass testing to diagnose new cases, and the conduction of prognostic tests for monitoring HIV progression. This is being done to meet the targets of the 95%: 95%: 95% UN AIDS goal which is to be achieved by 2025. Therefore, there is the need to discover other diagnostic and prognostic biomarkers to be supplemented with the currently used ones. Studies indicate that micro RNAs have their levels influenced by the presence and replication of aetiologic agents, thus the micro RNA (miRNA) expression profile test may serve the dual purpose of HIV diagnosis and prognosis. Therefore, this study assessed the HIV-1 diagnostic and prognostic potential of the expression patterns of circulating miRNAs in HIV positive persons in Cape Coast, Ghana.

methodsA cross-sectional research design was used to assess the expression patterns of seven miRNAs - hsa-mir-146a, hsa-mir-155, hsa-mir-34a, hsa-mir-29a, hsa-mir-29b, hsa-mir-223 and hsa-mir-27a in 72 plasma samples. The samples were obtained from six antiretroviral therapy naïve persons, 37 ART-experienced persons and 29 healthy controls. Total RNA was extracted, afterwards, cDNA synthesis and RT-qPCR was done.

resultsThere were low levels of hsa-mir-155, and elevated levels of two miRNAs - hsa-mir-34a, and hsa-mir-27a in ART-experienced persons relative to healthy control. The sensitivities of the above miRNAs were 82.14%, 72.73% and 81.25 respectively, and specificities were 86.21%, 70.59% and 87.50% respectively. Upregulated levels of hsa-mir-223 was associated with HIV-1 infection in ART-naïve persons. Hsa-mir-223, hsa-mir-155, hsa-mir-29a and hsa-mir29b were present in quantities that distinguished between viral load categories classified as very low and high. These miRNAs were correlated with viral load. Low levels of hsa-mir-155 in HIV-1 persons with viral load of less than 7cps/ml distinguished them from HIV-negative control. Increased levels of hsa-mir-146a correlated with ART-resistance.

conclusionDecreased levels of hsa-mir-155, and elevated levels of hsa-mir-34a, hsa-mir-223 and hsa-mir-27a could be biomarkers of HIV-1. Hsa-mir-155, hsa-mir-29a, hsa-mir29b and hsa-mir-223 could be good biomarkers of HIV-1 progression and Low levels of hsa-mir-155 may possess the potential to detect minute HIV-1 RNA copies. Elevated levels of hsa-mir-146a could be a potential biomarker of ART-resistance.

Indexed as

Anti-HIV AgentsDrug Resistance, ViralHIV-1HIV InfectionsMicroRNAsAdultBiomarkersCross-Sectional StudiesFemaleGhanaHumansMaleMiddle AgedPrognosisSensitivity and SpecificityViral LoadAnti-HIV AgentsBiomarkersMicroRNAsBiomarkerDiagnosisExpressionLevelsMicro RNAProgressionViral load

Identifiers

PMID40457240
PMCPMC12128229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.